

F. No. BIO/CT/20/000057
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Biological Division)

From,

The Drugs Controller General, India
Directorate General of Health Services,

FDA Bhawan, Kotla Road,
New Delhi-110002

To,

M/s Cadila Healthcare Limited,
Plot Survey No. 23, 25/P, 37, 40/P, 42 to 47,
Sarkhej-Bavla, N.H. No. 8A,
Opposite Ramdev Masala,
Village Changodar, Tal: Sanand,
Ahmedabad – 382 213, Gujarat.

Subject: Application for grant of permission to conduct Phase II clinical trial entitled “A phase II, randomized, controlled, open-label study to evaluate the efficacy and safety of PEGylated IFN alfa-2b in the treatment of adult patients diagnosed with SARS-Co V2 (COVID-19)”, vide Protocol No.: PEGI.20.002, Version No.: 02 Dated: 05.05.2020 – regarding

Sir,

With reference to your application No. BIO/CT04/FF/2020/19586, dated 02.05.2020, please find enclosed herewith the permission in FORM CT-06 for conduct of subject mentioned Phase II clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

- i. Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- ii. Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be,

shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- iii. In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- iv. The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- v. Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- vi. Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- vii. Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- viii. Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;
- ix. In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;
- x. Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- xi. In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;
- xii. In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;
- xiii. The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorised by the Central Licensing Authority,

to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

- xiv. Where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licensing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- xv. The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- xvi. The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- xvii. The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- xviii. Standard of care should be uniform to the fullest possible extent across both the arms throughout the trial. The same should be submitted to CDSCO before initiation of the trial.
- xix. Criteria of moderate patients as per ICMR should be included in the inclusion criteria.
- xx. Firm should submit revised protocol (including changes recommended in point no. xvii and xix above) to CDSCO before initiation of the subject study.

Yours faithfully


VENUGOPAL
 GIRDHARILAL SOMANI
 DN: c=IN, o=MINISTRY OF HOME
 Lp: 100, 1st Floor, 1st Block, 1st Wing,
 postalCode=431301, st=Maharashtra,
 23,4,20-1738031945-0924489832379a
 39911a7, cn=VENUGOPAL
 GIRDHARILAL SOMANI
 Date: 2020/03/11 18:12:56 +05'30'

(Dr. V. G. Soman)
 Drugs Controller General (India)
 Central Licensing Authority

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG**

The Central Licencing Authority hereby grants M/s Cadila Healthcare Limited, Zydus Research Center, Survey No. 396/403, Sarkhej-Bavla National Highway No. 8A Moraiya, Ahmedabad - 382213, India to conduct clinical trial of the new drug or investigational new drug as per vide Protocol No.: PEGI.20.002, Version No.: 02 Dated: 05.05.2020 in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].
3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date: 08.05.2020

VENUGOPAL
GIRDHARILAL
L SOMANI

(Dr. V. G. Soman)

Drugs Controller General (India)
Central Licensing Authority

Annexure:**Details of new drug or investigational new drug:**

Names of the new drug or investigational new drug	Pegylated interferon alfa-2b																														
Therapeutic class	Antiviral																														
Dosage form:	Parenteral (Lyophilized powder for solution for Injection). Prior to administration each vial is reconstituted with 0.7 ml of sterile WFI and 0.5 ml of reconstituted drug product solution is recommended for subcutaneous administration.																														
Composition:	<table border="1"> <thead> <tr> <th>Sr.No.</th> <th>Name of Ingredient</th> <th>Quantity per mL</th> <th>Referenced monograph</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>Pegylated interferon alfa-2b (rDNA Origin) (Active substance)</td> <td>100 µg or 160 µg or 200 µg or 240 µg or 300 µg</td> <td>In-house</td> </tr> <tr> <td>2</td> <td>Succinic acid (Buffer)</td> <td>1.18 mg</td> <td>NF</td> </tr> <tr> <td>3</td> <td>Lactose monohydrate (Stabilizer)</td> <td>105.00 mg</td> <td>NF</td> </tr> <tr> <td>4</td> <td>Polysorbate 80 (surfactant)</td> <td>0.10 mg</td> <td>NF, USP</td> </tr> <tr> <td>5</td> <td>Sodium hydroxide</td> <td>q.s to pH 6.8</td> <td>NF</td> </tr> <tr> <td>6</td> <td>Water for Injection</td> <td>q.s to 1 mL</td> <td>USP</td> </tr> </tbody> </table>			Sr.No.	Name of Ingredient	Quantity per mL	Referenced monograph	1	Pegylated interferon alfa-2b (rDNA Origin) (Active substance)	100 µg or 160 µg or 200 µg or 240 µg or 300 µg	In-house	2	Succinic acid (Buffer)	1.18 mg	NF	3	Lactose monohydrate (Stabilizer)	105.00 mg	NF	4	Polysorbate 80 (surfactant)	0.10 mg	NF, USP	5	Sodium hydroxide	q.s to pH 6.8	NF	6	Water for Injection	q.s to 1 mL	USP
Sr.No.	Name of Ingredient	Quantity per mL	Referenced monograph																												
1	Pegylated interferon alfa-2b (rDNA Origin) (Active substance)	100 µg or 160 µg or 200 µg or 240 µg or 300 µg	In-house																												
2	Succinic acid (Buffer)	1.18 mg	NF																												
3	Lactose monohydrate (Stabilizer)	105.00 mg	NF																												
4	Polysorbate 80 (surfactant)	0.10 mg	NF, USP																												
5	Sodium hydroxide	q.s to pH 6.8	NF																												
6	Water for Injection	q.s to 1 mL	USP																												
Indications:	Proposed for use in SARS-CoV-2 (COVID 19)																														

Details of clinical trial site:

S. No.	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1.	Department of Onco-Anaesthesia & Palliative Medicine, National Cancer Institute, Jhajjar, All India Institute of Medical Sciences, Badsa, Haryana – 124 105, India.	Institutional Ethics Committee, Room No. 102, 1 st Floor old OT block, All India Institute of Medical Sciences, Ansari Nagar, New Delhi – 110 029, India. EC Reg. No. <u>ECR/538/Inst/DL/2014/RR-17</u>	Dr. Anuja Pandit